The FDA has approved several new therapies this week, including Amylyx’s oral treatment for ALS, a fourth Avastin biosimilar, a new glaucoma treatment and another indication for Duxipent. The agency also accepted an NDA for therapy for rare immunodeficiency disease.
Watts, chief emergency management medical officer, director of global health and a pediatric emergency medicine physician at Children’s Mercy Kansas City, is one of 10 winners in this year's Emerging Industry Leaders series.
Jennifer Watts, M.D., M.P.H., chief emergency management medical officer, director of global health and a pediatric emergency medicine physician at Children’s Mercy Kansas City, a children’s hospital in Kansas City, Missouri is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
Russell, senior vice president of government markets at Priority Health, a health plan in Grand Rapids, Michigan, is one of 10 winners in this year's Emerging Industry Leaders series.
Joyce Chan Russell, MBA, senior vice president of government markets at Priority Health, a health plan in Grand Rapids, Michigan, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
Mechanic, director of telehealth and medical director at Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, is one of 10 winners in this year's Emerging Industry Leaders series.
Oren J Mechanic, M.D., MBA, M.P.H., director of telehealth and medical director at Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
McInerney, corporate director of population health and wellness coordination at AmeriHealth Caritas, headquartered in Philadelphia, is one of 10 winners in this year's Emerging Industry Leaders series.
Mairéad McInerney, M.S.W., LCSW, CCM, corporate director of population health, wellness coordination, at AmeriHealth Caritas, headquartered in Philadelphia, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
The integration into Rightway's modern PBM combines the transparent pricing of Cost Plus Drugs with Rightway's signature member experience, granting members direct access to the pharmacy.
Khatua, chief physician executive at Northshore Edward-Elmhurst Health, a health system based in Evanston, Illinois, is one of 10 winners in this year's Emerging Industry Leaders series.
Sanjeeb Khatua, M.D., MBA, M.P.H., chief physician executive at Northshore Edward-Elmhurst Health, a health system based in Evanston, Illinois, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
Bebtelovimab is available under an emergency use authorization, and the HHS is making doses available to those who are uninsured and underinsured.
Hu, president of Connected Networks at WellSky, a care coordination network headquartered in Boston, is one of 10 winners in this year's Emerging Industry Leaders series.
Lissy Hu, M.D., MBA, president of Connected Networks at WellSky, a care coordination network headquartered in Boston, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
Herrera, chief executive officer and co-founder of Yuvo Health, a technology-enabled administrative and managed-care solution for federally qualified health centers based in New York City, is one of 10 winners in this year's Emerging Industry Leaders series.
Cesar Herrera, MBA, M.P.H., chief executive officer and co-founder of Yuvo Health, a technology-enabled administrative and managed-care solution for federally qualified health centers based in New York City, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
The FDA approved a tumor agnostic treatment for cancer, a lower dose MRI contrast agent, the first generic of Tazorac gel, and a gene therapy for a rare disease. Advisory committees vote down poziotinib for NSCLC and Pepaxto for multiple myeloma and give positive vote for microbiotic-based C. diff therapy. The agency has accepted sNDA for Tukysa for HER2 positive colorectal cancer.
Gayles, chief health officer of Hazel Health, a pediatric physical and mental telehealth provider for K-12 schools, headquartered in San Francisco, is one of 10 winners in this year's Emerging Industry Leaders series.
Travis Gayles, M.D., Ph.D., chief health officer of Hazel Health, a pediatric physical and mental telehealth provider for K-12 schools, headquartered in San Francisco, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
LaFeir Fry, vice president of innovation operations at the Geisinger Health System in Danville, Pennsylvania, a regional healthcare provider and health plan, is one of 10 winners in this year's Emerging Industry Leaders series.
Emily LaFeir Fry, M.H.A., vice president of innovation operations at the Geisinger Health System in Danville, Pennsylvania, a regional healthcare provider and health plan, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare Executive feature.
Davidson, vice president, employee health medical operations, at Memorial Hermann Health System, in Houston is one of 10 winners in this year's Emerging Industry Leaders series.
Annamaria Macaluso Davidson, M.D., MBA, vice president, employee health medical operations, at Memorial Hermann Health System in Houston, is one of the 10 up-and-coming healthcare leaders featured in the annual Managed Healthcare feature.
World Health Organization said there is a lack of evidence of clinical effectiveness of the monoclonal antibodies Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.
Various groups, clinics and organizations have set up places for people without housing to recover from an injury, surgery and serious illness.
The FDA has approved new therapies for psoriasis and kidney dysfunction. The agency has also scheduled an advisory committee meeting for nonprescription birth control and accepted applications for longer-acting aripiprazole, Rett syndrome drug, and an enzyme replacement therapy. Additionally, Clovis has submits supplemental applications for Rubraca.
Long, the vice president of industry relations at IQVIA, gives his take on the lingering effects of the pandemic on the healthcare sector and pharmaceutical market.
